Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

Clin Cancer Res. 2015 Oct 1;21(19):4251-3. doi: 10.1158/1078-0432.CCR-15-1126. Epub 2015 Jul 13.

Abstract

T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Immunomodulation / drug effects
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • Translational Research, Biomedical

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • pembrolizumab